The number of cases of lymphocytic hypophysitis is small, although the condition is not rare. For optimal therapy, the correct diagnosis from imaging, immunological studies, and pathological findings from a pituitary biopsy is important. Recently, anti-Rabphilin antibody has been proposed to be a biomarker for lymphocytic infundibulo-neurohypophysitis. Immunological disorders such as anti-Pit-1 antibody syndrome are similar to the pathogenesis of lymphocytic hypophysitis. Moreover, recent immune checkpoint blockade such ipilimumab has been shown to induce anti-CTLA-4-related hypophysitis. In the future, elucidating the immunological mechanism and establishing a suitable therapy will be necessary for accurate long-term prognosis. (J Nippon Med Sch 2017; 84: 201 208) 
Introduction
The causes of hypopituitarism are various and have been extensively classified as tumor, inflammation, vascular accident, trauma, and congenital defects. In this article, pituitary inflammation, especially primary hypophysitis, is reviewed, including recent topics and our experience with cases. The etiology of primary hypophysitis is thought to be an autoimmune process, which pathogenesis is gradually turned out and new autoimmune process has been reported 1 . Although pituitary biopsy is the gold standard for correct diagnosis, the procedure is invasive and not acceptable to all patients.
Definition and Classification
Hypophysitis is classified into primary and secondary forms. Primary forms are characterized by inflammation confined to the pituitary due to unknown etiology, and are classified by histopathological findings or the involved structures. Secondary forms are due to pituitary inflammatory processes triggered by definite etiology or pituitary involvement concomitant with more generalized known systemic diseases ( Table 1) 
Clinical Presentation
Hypophysitis-related symptoms are headache, disturbances in visual acuity and the visual field, and hypopituitarism due to inflammation and compression of surrounding tissues by the enlarged pituitary. These symptoms are similar to those of pituitary adenomas. In nonfunctioning pituitary adenoma, growth hormone (GH) secretion is considered to be impaired early and first. In contrast, adrenocorticotropic hormone (ACTH) secretion is impaired first in most cases of hypophysitis 4 . Increased prolactin (PRL) levels are observed in both conditions, resulting in decreased luteinizing hormone/follicle stimulating hormone. In hypophysitis, hypogonadism also occurs by damage of gonadotrophs due to inflammation. Pituitary gland-specific factor 1a was also suggested as an autoantigen of APA 8 ; however, these antibodies are not specific to hypophysitis. Hypophysitis-induced hypopituitarism shows various combinations of pituitary hormone deficiency. One mechanism is the presence of antibodies to both the hypothalamus and pituitary. The occurrence of central diabetes insipidus (CDI) in patients with lymphocytic hypophysitis seems to be due to autoimmune hypothalamic involvement rather than an expansion of the pituitary inflammatory process. A search for arginine vasopressin (AVP) antibodies with the immunofluorescence method in these patients may help to identify patients who are prone to developing autoimmune CDI 9 . The detection of anti-hypothalamic antibody targeting corticotropin-releasing hormone ( CRH )secreting cells in some patients with GH/ACTH deficiency but with APA targeting only GH-secreting cells in-dicates that an autoimmune aggression to the hypothalamus is jointly responsible for their LAH 10 . Consequently, not only pituitary but also hypothalamic autoimmunity may contribute to anterior pituitary dysfunction in LAH.
LINH 11
LINH is an uncommon inflammatory disorder that is often reported in men. LINH selectively affects the posterior pituitary and the pituitary stalk, resulting in CDI, and is frequently accompanied by hyperprolactinemia.
Magnetic resonance imaging (MRI) findings are loss of the posterior pituitary bright spot and thickening of the infundibular stalk 12 . CDI is associated with other autoimmune endocrine conditions along with detection of autoantibodies to AVP-secreting cells (AVPcAb) in a few cases. AVPcAb alone is not a good diagnostic marker for LINH but serves as guide 13 and predictive marker of gestational or post-partum autoimmune CDI 14 We experienced a case of LINH. A 26-year-old female with polydipsia and polyuria was diagnosed with CDI.
MRI showed pituitary stalk thickening, suggesting the 
IgG4-related Hypophysitis
IgG4-related hypophysitis is thought to be a variant of physitis, suggesting that IgG4-related hypophysitis may not be rare 19 .
We experienced a case with CDI, amenorrhea, and right abducens nerve palsy, which was diagnosed as IgG4-related hypophysitis following a pituitary biopsy.
MRI findings showed hypophysitis spreading suprasellar and over the right cavernous sinus (Fig. 2) . Pituitary enlargement and cavernous infiltration decreased after glucocorticoid therapy (Fig. 2) . The right abducens nerve palsy disappeared, and menstruation resumed, however, CDI persisted (unpublished data). IgG4-related disease was first proposed as a cause of autoimmune pancreatitis in Japan 20 . Thereafter, most cases of IgG4-related hypophysitis have been reported in Japan 21 . Although the precise reason is unknown, racial differences, increased to MRI in Japan 22 may be the reasons.
Anti-Pit-1 Antibody Syndrome
Congenital combined TSH, GH, and PRL deficiency due to a Pit-1 gene mutation is a well-known cause of short stature and failure to develop 23 . Pit-1 is essential for the 26 .
We experienced a fourth case of anti-Pit-1 antibody
syndrome. An 85-year-old man with general malaise and peripheral edema was diagnosed with GH, PRL, and TSH deficiency. Circulating antibodies that reacted with Pit-1 were observed. However, he had no thymoma but multiple metastatic liver tumors for which the primary cancer was not known. This case may be associated with immune-related cytotoxicity due to paraneoplastic syndrome (unpublished data).
Immune Checkpoint Blockade-related Hypophysitis 27
Immune checkpoint blockade such as cytotoxic Tlymphocyte antigen 4 (CTLA-4) antibodies or programmed cell death protein 1 (PD-1) antibodies is now used for cancer therapy. Sometimes, immune-related adverse events (IRAEs) are recognized and one of the endocrine IRAEs is hypophysitis. Hypophysitis occurs at a frequency of 9.1% and generally at 6 12 weeks after treatment in older males. Secondary adrenal failure, hypothyroid, and hypogonadism are common but GH deficiency is assessed rarely. CDI was reported in only one case. PRL increases or decreases, and recovery of ACTH is less frequent. Cases with antibodies to pituitary cells were identified as LAH. The hypothesized mechanism is that IgG1, which activates the classic complement pathway, may be a mechanism of anti-CTLA-4-related hypophysitis, because CTLA-4 antibodies belong to the IgG1 class. Because pituitary swelling is followed by shrinkage, normal MRI does not rule out hypophysitis 28 . Unlike ipilimumab, nivolumab, a PD-1 antibody, has not been linked to an increased incidence of hypophysitis, which occurs in <1% of patients 27, 29 . The reason for the discrepancy in the occurrence rate between CTLA-4 antibodies and PD-1 antibodies is that pituitary cells express ectopic CTLA-4, resulting in CTLA-4 antibody-induced hypophysitis 30 .
Imaging Study
MRI findings in the case of hypophysitis indicate pituitary enlargement with symmetrical expansion and intense and homogeneous enhancement of the pituitary mass with gadolinium. Dural tail sign is positive, a condition seen on contrast-enhanced MRI as a thickening of the enhanced dura matter that resembles a tail extending from a mass 31 , although this sign is not specific to hypophysitis 32 . The pituitary stalk is thickened but not deviated. On the contrary, a unilateral endosellar mass, a nonhomogeneously expanding pituitary mass with asymmetrical extension, or delayed and nonhomogeneous enhancement suggests a pituitary adenoma. The pituitary stalk is deviated contralaterally in a pituitary adenoma 2 ( Table 3) .
We observed a case that was diagnosed as a pituitary adenoma from MRI findings, which showed a less enhanced lesion by gadolinium ( Fig. 3) . However, the pathological diagnosis was xantomatous hypophysitis (unpublised data). Therefore, differentiating pituitary Some anterior pituitary insufficiencies are resolved by glucocorticoids, even in a lower dose range 16 . In glucocorticoid-resistant cases, immunosuppressive drugs such as azathioprine, methotrexate, and cyclosporine A have been used successfully. However, the long-term effects are unclear 2 . Recently, rituximab, a monoclonal anti-body that lyses B cells expressing CD20, has been employed to treat steroid-refractory lymphocytic hypophysitis 35 and IgG4-related disease 36 , suggesting that rituximab could be considered a new option for the treatment of some types of LAH.
Hormone replacement : Glucocorticoid deficiency should be used first to avoid a potential adrenal crisis that may be precipitated by replacing thyroid hormone first. Because adrenal insufficiency may mask the presence of partial CDI, monitoring patients for the development of diabetes insipidus after starting glucocorticoid replacement has been suggested. Hormone replacement should be consistent with the current Endocrine Society Clinical Practice Guidelines 37 .
Treatment in the Future
No consensus treatment for lymphocytic hypophysitis has been established, and long-term outcomes are not known. Therefore, a prospective randomized study is desirable to further elucidate the best treatment, and longterm follow-up of the outcome in multiple institutes is necessary due to the low incidence of lymphocytic hypophysitis. Then, selection of an appropriate, personalized therapy for each type of hypophysitis and severity of symptoms may be possible.
